Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is expanding its capacity to manufacture antibody-drug conjugates—and that it has increased the scope of its partnership with a large, unnamed U.S. drugmaker.
Source: FiercePharma
